Adaptimmune Therapeutics (NASDAQ:ADAP) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP - Free Report) in a report issued on Wednesday. The firm issued a buy rating on the biotechnology company's stock.

Other equities research analysts have also issued research reports about the company. Jones Trading lowered Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 11th. Guggenheim reduced their price objective on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating for the company in a research report on Wednesday, March 26th. Scotiabank dropped their target price on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating on the stock in a research report on Friday, March 21st. Wells Fargo & Company reduced their price target on shares of Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating for the company in a research report on Friday, March 21st. Finally, HC Wainwright dropped their price objective on Adaptimmune Therapeutics from $3.50 to $3.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, Adaptimmune Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $1.83.

Adaptimmune Therapeutics Stock Up 3.9 %

Shares of Adaptimmune Therapeutics stock traded up $0.01 on Wednesday, reaching $0.29. 482,898 shares of the company were exchanged, compared to its average volume of 1,756,444. The stock's 50 day moving average price is $0.33 and its 200-day moving average price is $0.54. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. Adaptimmune Therapeutics has a 1-year low of $0.20 and a 1-year high of $1.48. The company has a market cap of $73.54 million, a P/E ratio of -1.30 and a beta of 2.86.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last posted its quarterly earnings results on Monday, March 24th. The biotechnology company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.09). Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. The firm had revenue of $3.22 million for the quarter, compared to analyst estimates of $16.56 million. As a group, equities analysts forecast that Adaptimmune Therapeutics will post -0.14 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ADAP. Invesco Ltd. grew its holdings in shares of Adaptimmune Therapeutics by 82.0% during the fourth quarter. Invesco Ltd. now owns 63,335 shares of the biotechnology company's stock worth $34,000 after buying an additional 28,526 shares during the last quarter. Two Sigma Advisers LP grew its stake in shares of Adaptimmune Therapeutics by 492.0% in the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 58,787 shares during the last quarter. Two Sigma Investments LP increased its holdings in shares of Adaptimmune Therapeutics by 33.5% in the fourth quarter. Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 19,146 shares during the period. Virtu Financial LLC raised its stake in shares of Adaptimmune Therapeutics by 21.5% during the fourth quarter. Virtu Financial LLC now owns 122,696 shares of the biotechnology company's stock worth $66,000 after purchasing an additional 21,688 shares during the last quarter. Finally, LPL Financial LLC lifted its holdings in shares of Adaptimmune Therapeutics by 106.5% during the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company's stock worth $99,000 after purchasing an additional 94,623 shares during the period. 31.37% of the stock is currently owned by institutional investors and hedge funds.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.